Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS’ Barry Straube Chats About Coverage-With-Evidence Development

This article was originally published in The Pink Sheet Daily

Executive Summary

Straube vows that CMS' coverage-with-evidence development policy will not be used to restrict coverage for new technologies.

You may also be interested in...

Allergan Bid For Device Firm Inamed Would Diversify Aesthetic Offerings

Purchase of Inamed would give Allergan entry into the facial aesthetics market and augment Allergan's Botox franchise. The $3.2 bil. offer for Inamed marks a $450 mil. premium over fellow bidder Medicis.

Digene Aims To Capitalize On Planned HPV Vaccine Launch In 2006

The firm is discussing partnerships with Merck, GSK to co-promote use of its HPV test with forthcoming human papillomavirus vaccines.

MedPAC Report Explores Ways For CMS To Use Cost-Effectiveness Analysis

Medicare Payment Advisory Commission’s June report to Congress suggests drug and device manufacturers that have completed cost-effectiveness analyses could share them with CMS. Advisory group also names possible federal agencies that might aid in conducting government-sponsored cost-effectiveness research for certain expensive medical products.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts